Company Update (NYSE:MRK): TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin , a placebo-controlled study of the . . . → Read More: Company Update (NYSE:MRK): TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes Similar Articles: Stock Update: Johnson & Johnson (NYSE:JNJ) – U.S. FDA warns on newer class of type 2 diabetes drugs Market Update (NYSE:LLY): U.S. FDA warns on newer class of type 2 diabetes drugs Market Update (NYSE:LLY): FDA approves Boehringer-Lilly drug for type-2 diabetes patients